Repatha and Cannabis Interaction Profile: What Patients and Clinicians Need to Know

How Evolocumab Is Metabolized (and Why CYP450 Inducers Cannot Touch It)

Evolocumab is a fully human IgG2 monoclonal antibody. Like all therapeutic monoclonal antibodies, it is cleared through two pathways: saturable target-mediated clearance (binding to circulating PCSK9 protein) and non-specific proteolytic catabolism by reticuloendothelial cells throughout the body [1]. Neither pathway involves the CYP3A4, CYP2C9, CYP1A2, or any other hepatic cytochrome P450 isoenzyme.

This is the single most important pharmacokinetic fact for any cannabis question about evolocumab.

Cannabis contains dozens of biologically active compounds, but the two clinically relevant ones for drug interactions are delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). THC is primarily metabolized by CYP3A4 and CYP2C9. CBD inhibits CYP3A4, CYP2C19, and CYP2D6 at clinically relevant concentrations [2]. Because evolocumab bypasses all CYP450 pathways entirely, none of these effects on hepatic enzymes translate into altered evolocumab exposure. The FDA prescribing information for Repatha makes no mention of any CYP-mediated interactions, consistent with the biology [3].

What the FDA Label Actually Says

The Repatha prescribing label states that no formal drug interaction studies have been conducted specifically with cannabis or cannabinoids, which is not unusual for a biologic cleared by proteolysis [3]. The absence of a listed interaction reflects the mechanistic impossibility of a PK interaction, not an oversight. Clinicians should interpret "no interaction listed" for evolocumab differently than they would for a small-molecule statin, where CYP-mediated interactions are common.

Protein Binding Is Not a Factor Either

Small-molecule drugs can interact by competing for plasma protein binding sites. Monoclonal antibodies like evolocumab are large proteins (approximately 144 kDa) that do not bind to albumin or alpha-1-acid glycoprotein in the same way. Displacement interactions that apply to warfarin or phenytoin do not apply here [1].

The Real Issue: Pharmacodynamic and Cardiovascular Risk Overlap

Cannabis and the Cardiovascular System

Even though evolocumab's clearance is unaffected by cannabis, the two interact at the clinical outcome level. Cannabis use produces measurable cardiovascular effects. Acute THC exposure increases resting heart rate by 20 to 100% and can raise systolic blood pressure, particularly during the first hour after use [4]. These acute hemodynamic changes increase myocardial oxygen demand.

A 2019 analysis published in the Journal of the American College of Cardiology found that daily or near-daily cannabis use was associated with an increased risk of major adverse cardiovascular events in younger adults (age <50), with adjusted hazard ratios reaching 1.93 for myocardial infarction in some subgroups [5]. Patients prescribed evolocumab almost always carry existing atherosclerotic cardiovascular disease or familial hypercholesterolemia. That is a population where hemodynamic stress has genuine clinical weight.

Cannabis and Lipid Levels

The relationship between cannabis and lipid parameters is more complicated than simply "cannabis raises cholesterol." Cross-sectional data from the National Health and Nutrition Examination Survey (NHANES) have found that current cannabis users tend to have slightly lower HDL-C and modestly higher triglycerides than non-users, though LDL-C effects are inconsistent across studies [6]. The 2020 ACC Expert Consensus Decision Pathway on tobacco and substance cessation notes that cannabis smoke contains many of the same particulate toxins as tobacco smoke, raising concerns about endothelial injury and plaque progression independent of lipid levels [7].

For a patient working to get LDL-C below the 55 mg/dL target recommended for very-high-risk ASCVD patients by the 2022 AHA/ACC guideline on lipid management, cannabis-driven triglyceride elevation is a secondary concern but still worth monitoring [8].

The Appetite Stimulation Angle

THC stimulates appetite through CB1 receptor agonism in the hypothalamus, an effect strong enough that the FDA approved dronabinol (synthetic THC) for HIV-related anorexia and chemotherapy-induced nausea [3]. In practice, patients who use cannabis regularly and experience appetite stimulation may find weight management harder, which can partially offset the LDL-C lowering achieved by evolocumab through lifestyle modification. This does not change the drug's efficacy, but it matters for the composite cardiovascular risk picture.

Evolocumab Efficacy Data: What You Are Protecting

Understanding the clinical stakes helps contextualize why any factor that adds cardiovascular risk deserves attention in evolocumab patients.

FOURIER Trial (N=27,564)

The landmark FOURIER trial enrolled 27,564 patients with established ASCVD already on optimized statin therapy. Evolocumab 140 mg every 2 weeks reduced LDL-C by a mean of 59% from baseline (median achieved LDL-C: 30 mg/dL vs. 92 mg/dL placebo). The primary composite endpoint (cardiovascular death, MI, stroke, hospitalization for unstable angina, or coronary revascularization) was reduced by 15% relative risk reduction (hazard ratio 0.85, 95% CI 0.79 to 0.92, P<0.001) over a median 2.2 years of follow-up [9].

The absolute risk reduction was modest at 1.5 percentage points, but clinically meaningful in a high-risk population. Adding avoidable cardiovascular stressors like acute hemodynamic surges from THC works against that benefit.

GLAGOV Trial (N=968)

The GLAGOV intravascular ultrasound trial demonstrated that evolocumab produced statistically significant regression of coronary atherosclerosis over 76 weeks (mean percent atheroma volume change: -0.95% evolocumab vs. +0.05% placebo, P<0.001) [10]. Plaque regression of this magnitude takes months to years of consistent therapy. Smoking or inhaling any combustion product, including cannabis smoke, promotes endothelial oxidative stress that may slow or reverse this process.

Can You Drink Alcohol While on Repatha?

The Short Answer

Moderate alcohol consumption does not create a pharmacokinetic interaction with evolocumab for the same structural reason cannabis does not: alcohol is metabolized by alcohol dehydrogenase and CYP2E1, neither of which touches monoclonal antibodies [3]. A glass of wine with dinner will not change how much evolocumab circulates in your blood.

The Nuanced Answer

Heavy or chronic alcohol use raises triglycerides through increased hepatic VLDL synthesis. A 2018 systematic review in Nutrition Reviews found that heavy drinking (defined as more than 3 drinks per day) raised fasting triglycerides by an average of 53 mg/dL compared to abstinence [11]. High triglyceride states can reduce LDL-C measurement accuracy when using Friedewald-equation calculations, complicating monitoring. Direct LDL-C measurement (not calculated) should be used in patients with triglycerides above 400 mg/dL.

Alcohol also adds hepatic oxidative burden. Evolocumab itself is hepatically benign, but patients on background statin therapy should note that heavy alcohol increases the risk of statin-associated myopathy through mechanisms involving oxidative stress and mitochondrial dysfunction [12].

Practical Guidance

The ACC/AHA 2019 guideline on the primary prevention of cardiovascular disease recommends limiting alcohol to no more than one drink per day for women and two for men as part of overall cardiovascular risk reduction [13]. This guidance applies to evolocumab patients independent of any drug-specific interaction.

Monitoring Framework for Cannabis-Using Patients on Evolocumab

Clinicians managing patients who use cannabis concurrently with evolocumab should organize monitoring around three areas: lipid response, cardiovascular hemodynamics, and lifestyle factors.

Lipid Panel Timing

Check a fasting lipid panel 4 to 8 weeks after initiating evolocumab or adjusting dose, then every 3 to 6 months once stable. In cannabis users, order a direct LDL-C measurement rather than relying on Friedewald calculation if triglycerides exceed 200 mg/dL, given the potential for cannabis-related triglyceride elevation to skew the result [8].

Blood Pressure and Heart Rate Surveillance

Patients who smoke or vaporize cannabis should have resting blood pressure and heart rate recorded at each clinic visit. Persistent resting tachycardia (heart rate above 100 bpm) or new-onset hypertension warrants formal substance use counseling. The 2022 ACC Consensus Statement on cannabis and cardiovascular health notes that "the evidence is sufficient to recommend that patients with established cardiovascular disease avoid cannabis use" [14].

Injection Site and Autoinjection Compliance

Evolocumab is delivered by subcutaneous injection via prefilled syringe or SureClick autoinjector. THC-related impairment at the time of scheduled injection is unlikely to affect drug stability but may affect patient technique or adherence. Patients should be counseled to administer their dose when sober and to rotate injection sites (abdomen, thigh, or upper arm) to minimize local reactions [3].

Statin Muscle Toxicity Overlap

Most evolocumab patients remain on background statin therapy. Cannabis has been reported anecdotally to interact with statin-associated myopathy, though high-quality trial data are limited. CBD at high doses inhibits OATP1B1, a hepatic uptake transporter relevant to atorvastatin and rosuvastatin pharmacokinetics. A 2020 case series in Clinical Pharmacology and Therapeutics described elevated rosuvastatin plasma concentrations in patients using high-dose CBD products [2]. Clinicians should ask about CBD supplement use specifically, as many patients do not volunteer it spontaneously.

Special Populations

Patients with Familial Hypercholesterolemia

Heterozygous FH affects approximately 1 in 250 adults and is characterized by LDL-C levels typically between 190 and 400 mg/dL from birth onward [15]. These patients often require evolocumab on top of maximally tolerated statin plus ezetimibe. Cardiovascular events can occur in the third and fourth decades of life. Cannabis use in this group carries the same pharmacodynamic concerns described above but with higher baseline risk, meaning each incremental cardiovascular stressor has greater absolute impact.

Pregnant and Lactating Patients

Cannabis use during pregnancy is associated with adverse fetal outcomes including low birth weight and neurodevelopmental delays [16]. Evolocumab's safety in pregnancy has not been established; the prescribing label advises discontinuation when pregnancy is confirmed [3]. This population is outside the scope of the interaction question but deserves mention because patients of reproductive age may be on evolocumab for FH.

Older Adults

Adults over 65 prescribed evolocumab for ASCVD secondary prevention represent a large portion of the treated population. Cannabis use in older adults is growing; the National Survey on Drug Use and Health reported that past-year cannabis use among adults aged 65 and older increased from 2.4% in 2015 to 4.2% in 2019 [17]. Older cardiovascular patients have reduced cardiac reserve, making acute THC-related tachycardia more consequential. Falls risk from THC-related dizziness or orthostatic hypotension is an additional concern in this group.

Key Guideline Positions

The 2022 AHA/ACC Guideline on the Management of Patients with Chronic Coronary Disease does not address cannabis specifically but states that "optimizing lifestyle behaviors, including smoking cessation, dietary modification, and physical activity, remains foundational to reducing residual cardiovascular risk in patients on evidence-based pharmacotherapy" [18].

The National Lipid Association's 2021 Scientific Statement on statin safety and associated adverse effects emphasizes that patients on lipid-lowering therapy should be counseled on all substances that may affect cardiovascular risk, even when no direct PK interaction with the medication exists [19].

"Patients who use cannabis should understand that the cardiovascular effects of THC are real and measurable, even if they do not alter the blood levels of their lipid medication," summarizes a position reflected across several ACC expert consensus documents [14].

Putting It Together: A Direct Clinical Summary

Evolocumab and cannabis do not interact pharmacokinetically. The drug's monoclonal antibody structure renders it immune to CYP450-mediated drug interactions, and no displacement or transporter-based interaction has been identified. Clinicians should not withhold or deprioritize evolocumab therapy because a patient uses cannabis.

The clinical concern is additive cardiovascular risk. Cannabis acutely stresses the cardiovascular system through tachycardia and blood pressure changes, and chronic use may worsen the lipid environment through triglyceride elevation and potential endothelial effects. Patients with ASCVD or FH using evolocumab carry elevated baseline cardiovascular risk that makes these pharmacodynamic concerns more clinically significant than they would be in a healthy young adult.

Patients using CBD-containing products (oils, capsules, high-dose edibles) should be specifically asked about dose and frequency, because high-dose CBD inhibits CYP3A4 and OATP1B1 and may affect co-administered statins even though evolocumab itself remains unaffected [2].

At the next follow-up visit, obtain a direct LDL-C, a fasting triglyceride level, and resting heart rate. If the patient is smoking cannabis, discuss transition to non-combustion delivery methods and provide brief motivational counseling aligned with the ACC tobacco and substance cessation pathway. The LDL-C target for very-high-risk ASCVD patients is <55 mg/dL per 2022 ACC/AHA guidance, and everything that works against reaching that target deserves a conversation [8].